Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License And Commercialization Agreement With Quadri Pharmaceuticals Store For Rare Intestinal Failure Diseases In Middle East Markets
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health, Inc. (NASDAQ:JAGX) has entered into a revenue sharing license and commercialization agreement with Quadri Pharmaceuticals Store LLC. The agreement grants Quadri Pharma exclusive rights to promote, commercialize, and distribute a powder formulation of crofelemer for rare intestinal failure diseases in multiple Middle East countries, following regulatory approval. Quadri Pharma will cover 50% of the development costs for the specified rare disease indications for three years.
November 02, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's new agreement with Quadri Pharma could potentially increase its revenue and expand its market reach in the Middle East.
The agreement with Quadri Pharma allows Jaguar Health to expand its market reach in the Middle East, which could potentially increase its revenue. Quadri Pharma's commitment to cover 50% of the development costs also reduces Jaguar Health's financial burden, which could positively impact its financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100